Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.49 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.49 |
| ▸ | FER | P16591 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16164072 | 0.90 | SYK (0.61) | SYKKCNH2AURKBMAPK3MAPK1 | |
| SCHEMBL16169314 | 0.89 | SYK (0.48) | SYKKCNH2AURKBMAPK3MAPK1 | |
| SCHEMBL16165499 | 0.89 | SYK (0.49) | SYKKCNH2AURKBMAPK3MAPK1 | |
| SCHEMBL16164454 | 0.86 | FER (0.39) | SYKKCNH2AURKBMAPK3MAPK1 | |
| SCHEMBL16165670 | 0.85 | SYK (0.51) | SYKKCNH2AURKBMAPK3MAPK1 | |
| SCHEMBL16165729 | 0.83 | SYK (0.45) | SYKKCNH2AURKBMAPK3MAPK1 | |
| SCHEMBL16165132 | 0.82 | SYK (0.49) | SYKKCNH2AURKBMAPK3MAPK1 | |
| SCHEMBL14910022 | 0.82 | SYK (0.58) | SYKKCNH2AURKBMAPK3MAPK1 | |
| SCHEMBL3387186 | 0.82 | SYK (0.58) | SYKKCNH2AURKBMAPK3MAPK1 | |
| SCHEMBL10250818 | 0.82 | SYK (0.58) | SYKKCNH2AURKBMAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2799431-B1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2018-01-24 | — | — | EP | disclosed |
| US-9051310-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2015-06-09 | — | — | US | disclosed |
| EP-2799431-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM Corporation (JP) | 2014-11-05 | — | — | EP | disclosed |
| US-20140309225-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309225-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, BTK, NOX4 | SYK 1/4885KCNH2 1953/4885AURKB 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.